Farallon Capital Management LLC Sage Therapeutics, Inc. Transaction History

Farallon Capital Management LLC

$19.9 Billion
Q3 2024

A detailed history of Farallon Capital Management LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 42,800 shares of SAGE stock, worth $234,544. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,800

Previous 42,800 -0.0%

Holding current value

$234,544

Previous $464,000 33.62%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $731,880 - $952,728	42,800 New	42,800 $927,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $716,900 - $2.1 Million	42,800 New	42,800 $880,000
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $49.8 Million - $68.2 Million	-705,000 Reduced 67.14%	345,000 $25.8 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $8.23 Million - $12.5 Million	200,000 Added 23.53%	1,050,000 $64.2 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $4.54 Million - $7.55 Million	175,000 Added 25.93%	850,000 $35.3 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $4.58 Million - $13.5 Million	175,000 Added 35.0%	675,000 $19.4 Million
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $7.65 Million - $19.7 Million	127,200 Added 34.12%	500,000 $36.1 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $17.8 Million - $24.2 Million	-127,200 Reduced 25.44%	372,800 $52.3 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $15.8 Million - $18.3 Million	-100,000 Reduced 16.67%	500,000 $91.5 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $17.9 Million - $32.7 Million	200,000 Added 50.0%	600,000 $95.4 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $18.4 Million - $31.4 Million	-225,000 Reduced 36.0%	400,000 $38.3 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $25.3 Million - $31.6 Million	180,000 Added 40.45%	625,000 $97.8 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $6.85 Million - $8.65 Million	45,000 Added 11.25%	445,000 $71.7 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $9.5 Million - $26.2 Million	156,500 Added 64.27%	400,000 $65.9 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $15 Million - $21.6 Million	243,500	243,500 $15.2 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.

Account

Farallon Capital Management LLC Sage Therapeutics, Inc. Transaction History